Obesity Clinical Trial
— STEP 5Official title:
Two-year Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity
Verified date | July 2023 |
Source | Novo Nordisk A/S |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will look at the change in body weight from the start to the end of the study. Researchers will compare the weight loss in people taking semaglutide (a new medicine) to people taking "dummy" medicine. In addition to taking the medicine, participants will also have talks with study staff about healthy food choices, how the participant can be more physically active and what participants can do to lose weight. Participants will either get semaglutide or "dummy" medicine - which treatment the participant gets is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The study will last for about 2 years. The participants will have 19 clinic visits and 15 phone calls with the study doctor.
Status | Completed |
Enrollment | 304 |
Est. completion date | March 23, 2021 |
Est. primary completion date | January 29, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Male or female, age more than or equal to 18 years at the time of signing informed consent - Body mass index (BMI) more than or equal to 30 kg/m^2 or more than or equal to 27 kg/m^2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease - History of at least one self-reported unsuccessful dietary effort to lose body weight Exclusion criteria: - HbA1c more than or equal to 48 mmol/mol (6.5%) as measured by the central laboratory at screening - A self-reported change in body weight more than 5 kg (11 lbs) within 90 days before screening irrespective of medical records |
Country | Name | City | State |
---|---|---|---|
Canada | Novo Nordisk Investigational Site | Halifax | Nova Scotia |
Canada | Novo Nordisk Investigational Site | Hamilton | Ontario |
Canada | Novo Nordisk Investigational Site | Hamilton | Ontario |
Canada | Novo Nordisk Investigational Site | Moncton | New Brunswick |
Canada | Novo Nordisk Investigational Site | Montreal | Quebec |
Canada | Novo Nordisk Investigational Site | Quebec | |
Canada | Novo Nordisk Investigational Site | Surrey | British Columbia |
Canada | Novo Nordisk Investigational Site | Toronto | Ontario |
Canada | Novo Nordisk Investigational Site | Toronto | Ontario |
Hungary | Novo Nordisk Investigational Site | Budapest | |
Hungary | Novo Nordisk Investigational Site | Budapest | |
Hungary | Novo Nordisk Investigational Site | Budapest | |
Hungary | Novo Nordisk Investigational Site | Debrecen | |
Hungary | Novo Nordisk Investigational Site | Komarom | |
Hungary | Novo Nordisk Investigational Site | Szekszárd | |
Italy | Novo Nordisk Investigational Site | Bologna | |
Italy | Novo Nordisk Investigational Site | Palermo | |
Italy | Novo Nordisk Investigational Site | Pisa | |
Italy | Novo Nordisk Investigational Site | Rome | |
Italy | Novo Nordisk Investigational Site | Siena | |
Spain | Novo Nordisk Investigational Site | Alcorcón | |
Spain | Novo Nordisk Investigational Site | Almeria | |
Spain | Novo Nordisk Investigational Site | Hospitalet de Llobregat | |
Spain | Novo Nordisk Investigational Site | Pamplona | |
Spain | Novo Nordisk Investigational Site | Pozuelo de Alarcon | |
Spain | Novo Nordisk Investigational Site | Sevilla | |
United States | Novo Nordisk Investigational Site | Albany | New York |
United States | Novo Nordisk Investigational Site | Arlington | Virginia |
United States | Novo Nordisk Investigational Site | Aurora | Colorado |
United States | Novo Nordisk Investigational Site | Austin | Texas |
United States | Novo Nordisk Investigational Site | Birmingham | Alabama |
United States | Novo Nordisk Investigational Site | Butte | Montana |
United States | Novo Nordisk Investigational Site | Golden | Colorado |
United States | Novo Nordisk Investigational Site | Jacksonville | Florida |
United States | Novo Nordisk Investigational Site | Kingsport | Tennessee |
United States | Novo Nordisk Investigational Site | Los Angeles | California |
United States | Novo Nordisk Investigational Site | Ocala | Florida |
United States | Novo Nordisk Investigational Site | Rochester | New York |
United States | Novo Nordisk Investigational Site | Round Rock | Texas |
United States | Novo Nordisk Investigational Site | Saint Peters | Missouri |
United States | Novo Nordisk Investigational Site | Waterbury | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Novo Nordisk A/S |
United States, Canada, Hungary, Italy, Spain,
Kushner RF, Calanna S, Davies M, Dicker D, Garvey WT, Goldman B, Lingvay I, Thomsen M, Wadden TA, Wharton S, Wilding JPH, Rubino D. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity (Silver Spring). 2020 Jun;28(6):1050-1061. doi: 10.1002/oby.22794. — View Citation
Wharton S, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jodar E, Kandler K, Rigas G, Wadden TA, Garvey WT. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity (Silver Spring). 2023 Mar;31(3):703-715. doi: 10.1002/oby.23673. Epub 2023 Jan 18. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage Change From Baseline (Week 0) to Week 104 in Body Weight | Percentage change in body weight for both in-trial and on-treatment observation period from baseline (week 0) to week 104 is presented. The outcome measure was evaluated based on the data from both in-trial and on-treatment periods. In-trial observation period: the uninterrupted time interval from randomisation to last contact with trial site. On-treatment observation period: the interval from first to last trial product administration plus 2 weeks of follow-up and excluding any period of temporary treatment interruption defined as >2 consecutive missed doses (corresponding to >2 weeks off-treatment). | From Baseline (Week 0) to Week 104 | |
Primary | Number of Participants Who Achieved (Yes/no): Body Weight Reduction More Than or Equal to 5% | Number of participants who achieved greater than or equal to (>=) 5% weight loss at 104 weeks is presented. In the reported data, 'Yes' infers the number of participants who have achieved >=5% weight loss, whereas 'No' infers the number of participants who have not achieved >=5% weight loss. The outcome measure was evaluated based on the data from both in-trial and on-treatment periods. In-trial observation period: the uninterrupted time interval from randomisation to last contact with trial site. On-treatment observation period: the interval from first to last trial product administration plus 2 weeks of follow-up and excluding any period of temporary treatment interruption defined as >2 consecutive missed doses (corresponding to >2 weeks off-treatment). | At Week 104 | |
Secondary | Number of Participants Who Achieved (Yes/no): Body Weight Reduction More Than or Equal to 10% | Number of participants who achieved >=10% weight loss at 104 weeks is presented. In the reported data, 'Yes' infers the number of participants who have achieved >=10% weight loss, whereas 'No' infers the number of participants who have not achieved >=10% weight loss. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from randomisation to last contact with trial site. | At Week 104 | |
Secondary | Number of Participants Who Achieved (Yes/no): Body Weight Reduction More Than or Equal to 15% | Number of participants who achieved >=15% weight loss at 104 weeks is presented. In the reported data, 'Yes' infers the number of participants who have achieved >=15% weight loss, whereas 'No' infers the number of participants who have not achieved >=15% weight loss. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from randomisation to last contact with trial site. | At Week 104 | |
Secondary | Number of Participants Who Achieved (Yes/no): Body Weight Reduction More Than or Equal to 20% | Number of participants who achieved >=20% weight loss at 104 weeks is presented. In the reported data, 'Yes' infers the number of participants who have achieved >=20% weight loss, whereas 'No' infers the number of participants who have not achieved >=20% weight loss. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from randomisation to last contact with trial site. | At Week 104 | |
Secondary | Change From Baseline (Week 0) to Week 104 in Waist Circumference | Change in waist circumference from baseline (week 0) to week 104 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from randomisation to last contact with trial site. | From Baseline (Week 0) to Week 104 | |
Secondary | Change From Baseline (Week 0) to Week 104 in Body Weight (kg) | Change in body weight from baseline (week 0) to week 104 in kilogram (kg) is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from randomisation to last contact with trial site. | From Baseline (Week 0) to Week 104 | |
Secondary | Change From Baseline (Week 0) to Week 104 in Body Mass Index (BMI) | Change in BMI from baseline (week 0) to week 104 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from randomisation to last contact with trial site. | From Baseline (Week 0) to Week 104 | |
Secondary | Change From Baseline (Week 0) to Week 104 in Systolic Blood Pressure | Change in systolic blood pressure from baseline (week 0) to week 104 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from randomisation to last contact with trial site. | From Baseline (Week 0) to Week 104 | |
Secondary | Change From Baseline (Week 0) to Week 104 in Diastolic Blood Pressure | Change in diastolic blood pressure from baseline (week 0) to week 104 is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from randomisation to last contact with trial site. | From Baseline (Week 0) to Week 104 | |
Secondary | Change in Total Cholesterol-ratio to Baseline | Change in total cholesterol from baseline (week 0) to week 104 measured in milligrams per deciliter (mg/dL) is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from randomisation to last contact with trial site. | From Baseline (Week 0) to Week 104 | |
Secondary | Change in High Density Lipoprotein (HDL) Cholesterol-ratio to Baseline | Change in HDL cholesterol from baseline (week 0) to week 104 measured in mg/dL is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from randomisation to last contact with trial site. | From Baseline (Week 0) to Week 104 | |
Secondary | Change in Low Density Lipoprotein (LDL) Cholesterol-ratio to Baseline | Change in LDL cholesterol from baseline (week 0) to week 104 measured in mg/dL is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from randomisation to last contact with trial site. | From Baseline (Week 0) to Week 104 | |
Secondary | Change in Very Low Density Lipoprotein (VLDL) Cholesterol-ratio to Baseline | Change in VLDL cholesterol from baseline (week 0) to week 104 measured in mg/dL is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from randomisation to last contact with trial site. | From Baseline (Week 0) to Week 104 | |
Secondary | Change in Free Fatty Acids-ratio to Baseline | Change in free fatty acids from baseline (week 0) to week 104 measured in mg/dL is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from randomisation to last contact with trial site. | From Baseline (Week 0) to Week 104 | |
Secondary | Change in Triglycerides-ratio to Baseline | Change in triglycerides from baseline (week 0) to week 104 measured in mg/dL is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from randomisation to last contact with trial site. | From Baseline (Week 0) to Week 104 | |
Secondary | Change in High Sensitivity C-reactive Protein (hsCRP)-Ratio to Baseline | Change in hsCRP from baseline (week 0) to week 104 measured in mg/dL is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from randomisation to last contact with trial site. | From Baseline (Week 0) to Week 104 | |
Secondary | Change in Glycated Haemoglobin (HbA1c) (Percent [%]) | Change in HbA1c from baseline (week 0) to week 104 in % is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from randomisation to last contact with trial site. | From Baseline (Week 0) to Week 104 | |
Secondary | Change From Baseline (Week 0) to Week 104 in HbA1c (mmol/Mol) | Change in HbA1c from baseline (week 0) to week 104 in millimole per mole (mmol/mol) is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from randomisation to last contact with trial site. | From Baseline (Week 0) to Week 104 | |
Secondary | Change From Baseline (Week 0) to Week 104 in Fasting Plasma Glucose (FPG) (mmol/L) | Change in FPG from baseline (week 0) to week 104 in millimoles per liter (mmol/L) is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from randomisation to last contact with trial site. | From Baseline (Week 0) to Week 104 | |
Secondary | Change From Baseline (Week 0) to Week 104 in FPG (mg/dL) | Change in FPG from baseline (week 0) to week 104 in mg/dL is presented. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from randomisation to last contact with trial site. | From Baseline (Week 0) to Week 104 | |
Secondary | Change in Fasting Serum Insulin-ratio to Baseline (Pmol/L) | Change in fasting serum insulin from baseline (week 0) to week 104 measured in picomole per liter (pmol) is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from randomisation to last contact with trial site. | From Baseline (Week 0) to Week 104 | |
Secondary | Change in Fasting Serum Insulin-ratio to Baseline (mIU/mL) | Change in fasting serum insulin from baseline (week 0) to week 104 measured in milli-international units per milliliter (mIU/mL) is presented as ratio to baseline. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from randomisation to last contact with trial site. | From Baseline (Week 0) to Week 104 | |
Secondary | Percentage Change From Baseline (Week 0) to Week 52 in Body Weight | Percentage change in body weight from baseline (week 0) to week 52 is presented. | From Baseline (Week 0) to Week 52 | |
Secondary | Change From Baseline (Week 0) to Week 52 in Body Weight (kg) | Change in body weight from baseline (week 0) to week 52 in kg is presented. | From Baseline (Week 0) to Week 52 | |
Secondary | Change From Baseline (Week 0) to Week 52 in Body Mass Index (BMI) | Change in BMI from baseline (week 0) to week 52 is presented. | From Baseline (Week 0) to Week 52 | |
Secondary | Change From Baseline (Week 0) to Week 52 in Waist Circumference | Change in waist circumference from baseline (week 0) to week 52 is presented. | From Baseline (Week 0) to Week 52 | |
Secondary | Number of Participants Who at 52 Weeks Achieved (Yes/no): Body Weight Reduction More Than or Equal to 5% | Number of participants who achieved >=5% weight loss at 52 weeks is presented. In the reported data, 'Yes' infers the number of participants who have achieved >=5% weight loss, whereas 'No' infers the number of participants who have not achieved >=5% weight loss. | At Week 52 | |
Secondary | Number of Participants Who at 52 Weeks Achieved (Yes/no): Body Weight Reduction More Than or Equal to 10% | Number of participants who achieved >=10% weight loss at 52 weeks is presented. In the reported data, 'Yes' infers the number of participants who have achieved >=10% weight loss, whereas 'No' infers the number of participants who have not achieved >=10% weight loss. | At Week 52 | |
Secondary | Number of Participants Who at 52 Weeks Achieved (Yes/no): Body Weight Reduction More Than or Equal to 15% | Number of participants who achieved >=15% weight loss at 52 weeks is presented. In the reported data, 'Yes' infers the number of participants who have achieved >=15% weight loss, whereas 'No' infers the number of participants who have not achieved >=15% weight loss. | At Week 52 | |
Secondary | Number of Participants Who at 52 Weeks Achieved (Yes/no): Body Weight Reduction More Than or Equal to 20% | Number of participants who achieved >=20% weight loss at 52 weeks is presented. In the reported data, 'Yes' infers the number of participants who have achieved >=20% weight loss, whereas 'No' infers the number of participants who have not achieved >=20% weight loss. | At Week 52 | |
Secondary | Number of Treatment-emergent Adverse Events (TEAEs) | An adverse event (AE) was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. All AEs mentioned here are TEAE defined as an event that had onset date (or increase in severity) on or after the first day of exposure to treatment. The outcome measure was evaluated based on the data from on-treatment observation period, which was defined as the interval from first to last trial product administration plus 7 weeks of follow-up and excluding any period of temporary treatment interruption defined as >7 consecutive missed doses (corresponding to >7 weeks off-treatment). | From Baseline (Week 0) to Week 111 | |
Secondary | Number of Serious Adverse Events (SAEs) | A SAE was defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. The SAEs occurred from week 0 to week 111 is presented. The outcome measure was evaluated based on the data from on-treatment observation period, which was defined as the interval from first to last trial product administration plus 7 weeks of follow-up and excluding any period of temporary treatment interruption defined as >7 consecutive missed doses (corresponding to >7 weeks off-treatment). | From Baseline (Week 0) to Week 111 | |
Secondary | Change From Baseline (Week 0) to Week 104 in Pulse | Change in pulse from baseline (week 0) to week 104 is presented. The outcome measure was evaluated based on the data from on-treatment observation period, which was defined as the interval from first to last trial product administration plus 2 weeks of follow-up and excluding any period of temporary treatment interruption defined as >2 consecutive missed doses (corresponding to >2 weeks off-treatment). | From Baseline (Week 0) to Week 104 | |
Secondary | Change From Baseline (Week 0) to Week 104 in Amylase | Change in amylase from baseline (week 0) to week 104 is presented. The outcome measure was evaluated based on the data from on-treatment observation period, which was defined as the interval from first to last trial product administration plus 2 weeks of follow-up and excluding any period of temporary treatment interruption defined as >2 consecutive missed doses (corresponding to >2 weeks off-treatment). | From Baseline (Week 0) to Week 104 | |
Secondary | Change From Baseline (Week 0) to Week 104 in Lipase | Change in lipase from baseline (week 0) to week 104 is presented. The outcome measure was evaluated based on the data from on-treatment observation period, which was defined as the interval from first to last trial product administration plus 2 weeks of follow-up and excluding any period of temporary treatment interruption defined as >2 consecutive missed doses (corresponding to >2 weeks off-treatment). | From Baseline (Week 0) to Week 104 | |
Secondary | Change From Baseline (Week 0) to Week 104 in Calcitonin | Change in calcitonin from baseline (week 0) to week 104 is presented. The outcome measure was evaluated based on the data from on-treatment observation period, which was defined as the interval from first to last trial product administration plus 2 weeks of follow-up and excluding any period of temporary treatment interruption defined as >2 consecutive missed doses (corresponding to >2 weeks off-treatment). | From Baseline (Week 0) to Week 104 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |